We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Possible Tumor Growth Mechanism Found

By Biotechdaily staff writers
Posted on 28 Dec 2005
Scientists at have found an intrinsic characteristic of stem and progenitor cells that may trigger initiation and progression of cancerous tumors. More...


In a study published in the December 2005 issue of the journal Cancer Cell, a group of researchers from Columbia University Medical Center (CUMC, New York, NY, USA) reported that stem and progenitor cells are vulnerable to a certain error during cell division that can result in serious chromosomal defects. This susceptibility may explain how a tumor-initiating cell, also known as a cancer stem cell, arises from a normal cell. It may also clarify how a cancer stem cell acquires further mutations that increase tumor malignancy.

According to Timothy Bestor, Ph.D., and Marc Damelin, Ph.D., of Columbia University College of Physicians and Surgeons, understanding the character of cancer stem cells could result in new therapies that specifically target those cells, which are believed to be the underlying cause of tumor progression.

The process of cell division is closely tracked by the cell, because an error can result in cancer-causing chromosome abnormalities. Normally, during cell division, cells monitor quality control with a series of safeguards. One such safeguard confirms that the cell's chromosomes have been unscrambled before they are to be pulled apart in mitosis, to ensure that the chromosomes will be separated appropriately.

The researchers discovered, however, that stem and progenitor cells are deficient in this safeguard and will divide even if the chromosomes are entangled. All three cell types evaluated by the researchers--mouse embryonic stem cells, mouse neural progenitor cells, and human bone marrow progenitor cells--attempted cell division with entangled chromosomes. The investigators believe it likely that cancer stem cells, which closely resemble normal stem cells, have the same deficiency.

"The failure to untangle before dividing undoubtedly will lead to chromosomal defects,” stated Dr. Bestor, professor of genetics and development at Columbia and the study's chief investigator. "Surviving cells may end up with too many chromosomes, they may lose chromosomes, or some chromosomes may get rearranged.” These same kinds of chromosomal defects are the hallmark of cancer cells, and there are chromosomal defects in all types of cancer.

"We may have found how a stem cell without any pre-existing mutation can become a cancer stem cell,” noted Dr. Damelin, a CUMC postdoctoral fellow of the Damon Runyon Cancer Research Foundation and the lead author on the study.

The study also demonstrates the potential problems involved with stem cell therapies. In the lab, stem cells are stimulated to divide many times more than they typically would divide in an organism. The more stem cells divide, the more apt they are to acquire abnormal chromosome characteristics. However, the investigators reported that additional studies will be needed to understand and address these risks.






Related Links:
Columbia University Medical Center

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.